Original from: 360dx The Bill & Melinda Gates Foundation awarded more than 500 new grants in the fourth quarter of 2024, many of which are related to diagnostic and omics projects. The following is a..

Original from: Medical Device Network Health Canada has granted approval to MedMira’s Multiplo Rapid TP/HIV Test, for HIV and syphilis in Canada. The test enables healthcare professionals ..

Original from: CDC CDC continues to expect the respiratory disease season will have a similar or lower number of combined peak hospitalizations due to COVID-19, influenza, and RSV compared to last season..

Original from: FIERCE Biotech Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. The life sciences fund is XGEN’s first, and the m..

Original from: genomeweb Real-world data firm Cota said Thursday that it has teamed up with Guardant Health to provide biopharmaceutical researchers access to a combined database that will include its ow..

Original from: genomeweb Illumina and Macrogen announced on Monday that they are collaborating to sequence and analyze 145,952 genomes as part of South Korea's National Bio Big Data project. ..

On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promo..

Original from: business wire Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in develo..

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into a comprehensive strategic agreement with Graves Gilbert Clinic to manage the lab operations of its main full-service laboratory in Bowling Green, Kentucky, and its location in Glasgow, Kentucky.

2.4 Pertussis Diagnosis Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics. In recent years, the incidence of pertussis in children has increas..

Ovation.io, Inc., an organization dedicated to building best in class multi-omics datasets, today announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that will work to accelerate advancements in precision medicine. The collaboration will address challenges in drug development by harnessing the power of genomic data to enable the discovery of drug targets coupled with biomarkers that increase the probability of success and decrease the cost of development.

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.

Sansure Biotech’s Monkeypox virus nucleic acid testing kit approved for market launch Recently, the Monkeypox Virus Nucleic Acid Testing Kit (PCR-Fluorescent Probe Method) independently developed by San..

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network.

Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.